Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - epoprostenol sodium, quantity: 1.593 mg (equivalent: epoprostenol, qty 1.5 mg) - injection, powder for - excipient ingredients: sucrose; sodium hydroxide; glycine - epoprostenol sun is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii or class iv patients with idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.

United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - epoprostenol sodium (unii: 4k04iq1of4) (epoprostenol - unii:dcr9z582x0) - epoprostenol 0.5 mg - epoprostenol sodium for injection is indicated for the treatment of pulmonary arterial hypertension (pah) (who group i) to improve exercise capacity. trials establishing effectiveness included predominantly (97%) patients with new york heart association (nyha) functional class iii-iv symptoms and etiologies of idiopathic or heritable pah (49%) or pah associated with connective tissue diseases (51%). epoprostenol is contraindicated in patients with heart failure caused by reduced left ventricular ejection fraction [see clinical studies ( 14.3)] . epoprostenol is contraindicated in patients with a hypersensitivity to the drug or any of its ingredients. risk summary limited published data from case series and case reports have not established an association with epoprostenol and major birth defects, miscarriage or adverse maternal or fetal outcomes when epoprostenol is used during pregnancy. there are risks to the mother and fetus from untreated pulmonary arterial hypertension (see clinical considerations) . in

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - epoprostenol sodium, quantity: 1.593 mg (equivalent: epoprostenol, qty 1.5 mg) - injection, powder for - excipient ingredients: sodium chloride; sodium hydroxide; mannitol; glycine - flolan is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii or class iv patients with: idiopathic pulmonary arterial hypertension; familial pulmonary arterial hypertension; pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - epoprostenol sodium, quantity: 0.531 mg (equivalent: epoprostenol, qty 0.5 mg) - injection, powder for - excipient ingredients: sodium chloride; sodium hydroxide; mannitol; glycine - flolan is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii or class iv patients with: idiopathic pulmonary arterial hypertension; familial pulmonary arterial hypertension; pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - epoprostenol sodium, quantity: 0.531 mg (equivalent: epoprostenol, qty 0.5 mg) - injection, powder for - excipient ingredients: sucrose; sodium hydroxide; glycine - epoprostenol sun is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii or class iv patients with idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.

United States - English - NLM (National Library of Medicine)

actelion pharmaceuticals us, inc. - epoprostenol sodium (unii: 4k04iq1of4) (epoprostenol - unii:dcr9z582x0) - epoprostenol sodium 1500000 ng in 10 ml

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - epoprostenol sodium (unii: 4k04iq1of4) (epoprostenol - unii:dcr9z582x0) - epoprostenol for injection is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise capacity. studies establishing effectiveness included predominantly patients with nyha functional class iii-iv symptoms and etiologies of idiopathic or heritable pah or pah associated with connective tissue diseases. a large study evaluating the effect of epoprostenol on survival in nyha class iii and iv patients with congestive heart failure due to severe left ventricular systolic dysfunction was terminated after an interim analysis of 471 patients revealed a higher mortality in patients receiving epoprostenol plus conventional therapy than in those receiving conventional therapy alone. the chronic use of epoprostenol for injection in patients with congestive heart failure due to severe left ventricular systolic dysfunction is therefore contraindicated. some patients with pulmonary hypertension have developed pulmonary edema during dose initiation, which may be associated with

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - epoprostenol sodium, quantity: 531 microgram (equivalent: epoprostenol, qty 500 microgram) - powder - excipient ingredients: arginine; sodium hydroxide; sucrose - veletri is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii or class iv patients with:,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with the scleroderma spectrum of diseases

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - epoprostenol sodium, quantity: 1.593 mg (equivalent: epoprostenol, qty 1.5 mg) - powder - excipient ingredients: arginine; sodium hydroxide; sucrose - veletri is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii or class iv patients with:,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with the scleroderma spectrum of diseases

United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - epoprostenol sodium (unii: 4k04iq1of4) (epoprostenol - unii:dcr9z582x0) - epoprostenol 0.5 mg - flolan is indicated for the treatment of pulmonary arterial hypertension (pah) (who group i) to improve exercise capacity. trials establishing effectiveness included predominantly (97%) patients with new york heart association (nyha) functional class iii-iv symptoms and etiologies of idiopathic or heritable pah (49%) or pah associated with connective tissue diseases (51%). flolan is contraindicated in patients with heart failure caused by reduced left ventricular ejection fraction [see clinical studies (14.3)] . flolan is contraindicated in patients with a hypersensitivity to the drug or any of its ingredients. risk summary limited published data from case series and case reports have not established an association with flolan and major birth defects, miscarriage or adverse maternal or fetal outcomes when flolan is used during pregnancy. there are risks to the mother and fetus from untreated pulmonary arterial hypertension (see clinical considerations) . in animal reproduction studies, pregnant rats and rabbi